Sola

Quote

Anonymous

Guest
Good reviews are jumping stock price!
If we run another trial in only mild patients, could we be selling this in a couple years? or will the approval process take alot longer?
Anyone with insight....
 






Anonymous said:
Good reviews are jumping stock price!
If we run another trial in only mild patients, could we be selling this in a couple years? or will the approval process take alot longer?
Anyone with insight....
Click to expand...

I think it would take a lot longer. Lilly needs to 1) convince regulatory bodies to accept a trial with only cognition as endpoint, right now US and Europe require cognition + functional outcome. 2) run a second trial - probably very large, around the size of the two previous studies combined, and be positive 3) convince the partner (Quintiles) to continue on.
 
























The problem is that Roche and Baxter won't hire big pharma reps from companies like Lilly as a rule- of course it happens but its rare. They want proven sales people not people that work in pods and get paid a CVM bonus.
 












Anonymous said:
The problem is that Roche and Baxter won't hire big pharma reps from companies like Lilly as a rule- of course it happens but its rare. They want proven sales people not people that work in pods and get paid a CVM bonus.
Click to expand...

EXACTLY right! The only company Lilly reps will be attractive to now is GSK!
 












Anonymous said:
Good reviews are jumping stock price!
If we run another trial in only mild patients, could we be selling this in a couple years? or will the approval process take alot longer?
Anyone with insight....
Click to expand...

There is no way we will be selling it! In fact, it would be a slap in the face after selling Zyprexa and Symbyax. I would be embarrassed. Btw, not only did we not meet primary endpoints, but we didn't even seperate from Risperdal! Which makes you wonder..... why they didn't run the trial against Zyprexa seeing how it works so well (no I am not blind, it has side effects, but patients that sick need something to work and then you manage the side effects). When we sold Symbyax, our trials were against Zyprexa. Makes you wonder if they knew from the beginning that we had an inferior product.
 






Anonymous said:
There is no way we will be selling it! In fact, it would be a slap in the face after selling Zyprexa and Symbyax. I would be embarrassed. Btw, not only did we not meet primary endpoints, but we didn't even seperate from Risperdal! Which makes you wonder..... why they didn't run the trial against Zyprexa seeing how it works so well (no I am not blind, it has side effects, but patients that sick need something to work and then you manage the side effects). When we sold Symbyax, our trials were against Zyprexa. Makes you wonder if they knew from the beginning that we had an inferior product.
Click to expand...

You are D-U-M, dumb! This thread is ABAB not mGlu 2/3.
 












Anonymous said:
Not dumb, simply got the drugs mixed up. My bad. Lately in Neuro they keep talking about the schizophrenia drug going through trials again. Which would simply be a waste of money
Click to expand...

Not dumb, just got the drugs mixed up... "my bad" ???

The only drugs you need are smart drugs. Nope, not Lilly drugs, sorry. And even if they were, you would still have to pay for them.
 






Top Bottom
Back
Quote